Julie Chao to Male
This is a "connection" page, showing publications Julie Chao has written about Male.
Connection Strength
1.122
-
Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice. J Am Heart Assoc. 2018 11 06; 7(21):e009562.
Score: 0.034
-
Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway. Aging Cell. 2017 08; 16(4):837-846.
Score: 0.031
-
Kallistatin suppresses cancer development by multi-factorial actions. Crit Rev Oncol Hematol. 2017 May; 113:71-78.
Score: 0.030
-
Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Sep 18; 3(5):e001194.
Score: 0.026
-
Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014 Jun; 142(2):216-26.
Score: 0.025
-
Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol. 2012 Oct 15; 303(8):F1230-8.
Score: 0.022
-
Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010 Nov; 299(5):H1419-27.
Score: 0.019
-
Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem. 2010 Jul; 391(7):803-12.
Score: 0.019
-
Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 2010 Aug; 56(2):260-7.
Score: 0.019
-
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F1033-40.
Score: 0.018
-
Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol. 2010 Mar; 298(3):H1048-54.
Score: 0.018
-
Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 2009 Sep; 297(3):H1040-7.
Score: 0.018
-
Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1735-43.
Score: 0.017
-
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
Score: 0.017
-
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008 Dec 01; 80(3):354-64.
Score: 0.017
-
Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
Score: 0.017
-
Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008 Jun; 389(6):725-30.
Score: 0.016
-
Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008 May; 51(5):1358-65.
Score: 0.016
-
Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
Score: 0.016
-
Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008 Jan 16; 82(3-4):156-65.
Score: 0.016
-
Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol. 2007 Nov; 34(11):2171-6.
Score: 0.016
-
Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
Score: 0.015
-
Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
Score: 0.015
-
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007 Jan 01; 73(1):130-42.
Score: 0.015
-
Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther. 2006 May; 17(5):545-55.
Score: 0.014
-
Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr; 47(4):752-61.
Score: 0.014
-
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
Score: 0.014
-
Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
Score: 0.014
-
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F622-31.
Score: 0.013
-
Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
Score: 0.013
-
Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 2005 Apr; 52(4):1319-24.
Score: 0.013
-
Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
Score: 0.013
-
Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004 Aug; 66(2):722-32.
Score: 0.013
-
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
Score: 0.012
-
Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004 Jan; 43(1):109-16.
Score: 0.012
-
Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1479-88.
Score: 0.012
-
Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
Score: 0.012
-
Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol. 2003 06; 284(6):C1604-13.
Score: 0.012
-
Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2002 Aug 01; 22(8):1279-85.
Score: 0.011
-
Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides. 2001 Nov; 22(11):1731-7.
Score: 0.010
-
Protective role of kallistatin in renal fibrosis via modulation of Wnt/?-catenin signaling. Clin Sci (Lond). 2021 02 12; 135(3):429-446.
Score: 0.010
-
Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther. 2000 Sep 01; 11(13):1817-27.
Score: 0.010
-
Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension. 2000 Sep; 36(3):364-70.
Score: 0.010
-
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
Score: 0.010
-
Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res. 2000 Mar 03; 86(4):418-24.
Score: 0.009
-
Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol. 2000 Mar; 278(3):F484-91.
Score: 0.009
-
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
Score: 0.009
-
Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology. 1999 Oct 15; 44(1-2):137-43.
Score: 0.009
-
Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens. 1999 Oct; 21(7):1145-60.
Score: 0.009
-
Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke. 1999 Sep; 30(9):1925-31; discussion 1931-2.
Score: 0.009
-
Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999 Aug; 34(2):164-70.
Score: 0.009
-
Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol. 1999 03; 276(3):F476-84.
Score: 0.009
-
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int. 1998 Oct; 54(4):1250-60.
Score: 0.008
-
Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 1998 May; 53(5):1305-13.
Score: 0.008
-
Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension. 1998 May; 31(5):1104-10.
Score: 0.008
-
Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun. 1998 Mar 17; 244(2):449-54.
Score: 0.008
-
Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther. 1998 Jan 01; 9(1):21-31.
Score: 0.008
-
Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat. Am J Physiol. 1997 11; 273(5):F783-9.
Score: 0.008
-
Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther. 1997 Oct 10; 8(15):1753-61.
Score: 0.008
-
Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997 Sep; 30(3 Pt 1):307-13.
Score: 0.008
-
Kallistatin is a potent new vasodilator. J Clin Invest. 1997 Jul 01; 100(1):11-7.
Score: 0.008
-
Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice. Biochem J. 1997 Jul 01; 325 ( Pt 1):111-6.
Score: 0.008
-
Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology. 1997 Jun; 36(2-3):221-7.
Score: 0.008
-
Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol. 1997 Jun; 75(6):750-6.
Score: 0.008
-
Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS One. 2017; 12(5):e0178387.
Score: 0.008
-
Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci. 1997; 60(17):1431-5.
Score: 0.007
-
Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem. 1996 Nov 01; 271(44):27590-4.
Score: 0.007
-
Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res. 1996 Nov; 15(11):1117-23.
Score: 0.007
-
High-salt diet upregulates kininogen and downregulates tissue kallikrein expression in Dahl-SS and SHR rats. Am J Physiol. 1996 Oct; 271(4 Pt 2):F824-30.
Score: 0.007
-
Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol. 1996 Jul; 271(1 Pt 2):F78-86.
Score: 0.007
-
Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med. 1996 Jun; 127(6):612-20.
Score: 0.007
-
Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem. 1995 Jun 02; 270(22):13483-9.
Score: 0.007
-
Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. Gene. 1994 Nov 18; 149(2):283-8.
Score: 0.006
-
Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem. 1994 Jul 22; 269(29):18843-8.
Score: 0.006
-
Adenovirus-mediated eNOS expression augments liver injury after ischemia/reperfusion in mice. PLoS One. 2014; 9(3):e93304.
Score: 0.006
-
Subcellular distribution of tissue kallikrein and Na,K-ATPase alpha-subunit in rat parotid striated duct cells. Cell Tissue Res. 1994 Mar; 275(3):407-17.
Score: 0.006
-
Tissue kallikrein is related to the severity of coronary artery disease. Clin Chim Acta. 2013 Aug 23; 423:90-8.
Score: 0.006
-
Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
Score: 0.006
-
Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care. 2013 Feb 08; 17(1):R27.
Score: 0.006
-
Biochemical characterization and substrate specificity of rat prostate kallikrein (S3): comparison with tissue kallikrein, tonin and T-kininogenase. Biochim Biophys Acta. 1992 Jun 24; 1121(3):309-16.
Score: 0.005
-
Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992 Jun 15; 1131(2):145-51.
Score: 0.005
-
Tissue kallikrein activation of the epithelial Na channel. Am J Physiol Renal Physiol. 2012 Aug 15; 303(4):F540-50.
Score: 0.005
-
Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 2012 Aug; 23(8):859-70.
Score: 0.005
-
Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer. 2010 May 31; 10:245.
Score: 0.005
-
Purification and characterization of a kallikrein-like T-kininogenase. J Biol Chem. 1990 Feb 15; 265(5):2822-7.
Score: 0.005
-
Molecular cloning and primary structure of rat alpha 1-antitrypsin. Biochemistry. 1990 Jan 16; 29(2):323-9.
Score: 0.005
-
Sex dimorphism and inflammatory regulation of T-kininogen and T-kininogenase. Biochim Biophys Acta. 1989 Jun 27; 991(3):477-83.
Score: 0.004
-
Urinary prostasin: a possible biomarker for renal pressure natriuresis in black adolescents. Pediatr Res. 2009 Apr; 65(4):443-6.
Score: 0.004
-
Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther. 2009 Feb; 20(2):147-58.
Score: 0.004
-
Sex dimorphism and estrogen regulation of kininogens in rat serum, adrenal gland and kidney. Adv Exp Med Biol. 1989; 247B:297-303.
Score: 0.004
-
Prostasin: a possible candidate gene for human hypertension. Am J Hypertens. 2008 Sep; 21(9):1028-33.
Score: 0.004
-
Tissue distribution and kininogen gene expression after acute-phase inflammation. Biochim Biophys Acta. 1988 Mar 17; 964(3):329-39.
Score: 0.004
-
Identification and expression of kallikrein gene family in rat submandibular and prostate glands using monoclonal antibodies as specific probes. Biochim Biophys Acta. 1987 Dec 08; 910(3):233-9.
Score: 0.004
-
Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007 Jul; 28(7):1383-9.
Score: 0.004
-
Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
Score: 0.004
-
Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med. 2006 Oct 15; 41(8):1304-14.
Score: 0.004
-
Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. Am J Physiol Renal Physiol. 2006 Sep; 291(3):F567-77.
Score: 0.004
-
Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol. 2006 Feb; 197(2):521-30.
Score: 0.003
-
Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005 May; 54(5):1573-80.
Score: 0.003
-
Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
Score: 0.003
-
Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. J Gene Med. 2004 Jul; 6(7):786-97.
Score: 0.003
-
Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 Jun; 24(6):1104-10.
Score: 0.003
-
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov; 42(5):1026-33.
Score: 0.003
-
Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers. Prostate. 2003 Feb 15; 54(3):187-93.
Score: 0.003
-
Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats. Am J Physiol Regul Integr Comp Physiol. 2003 Apr; 284(4):R1031-6.
Score: 0.003
-
Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem. 2002 Sep 20; 277(38):34708-16.
Score: 0.003
-
Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation. 2002 Jan 01; 105(1):67-72.
Score: 0.003
-
Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2001 Jun; 280(6):F964-71.
Score: 0.003
-
Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000 Dec; 36(6):995-1001.
Score: 0.002
-
Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999 Oct 15; 44(1-2):57-65.
Score: 0.002
-
Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 Jun; 14(6):1376-84.
Score: 0.002
-
Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999 Jan; 33(1 Pt 2):219-24.
Score: 0.002
-
Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998 Jul 01; 9(10):1429-38.
Score: 0.002
-
Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 1997 Mar; 38(3):658-64.
Score: 0.002
-
Expression and localization of human kallistatin in rat submandibular gland after intracapsular gene injection. Biochem Biophys Res Commun. 1997 Feb 13; 231(2):494-8.
Score: 0.002
-
Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995 Dec; 26(6 Pt 1):847-53.
Score: 0.002
-
Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension. 1995 Apr; 25(4 Pt 2):715-9.
Score: 0.002
-
Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 1994 Sep 15; 23(2):362-9.
Score: 0.002
-
Molecular cloning and characterization of rKlk10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. Biochemistry. 1992 Nov 10; 31(44):10922-8.
Score: 0.001
-
Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. 1992 Apr; 41(4):789-95.
Score: 0.001
-
Characterization of genes encoding rat tonin and a kallikrein-like serine protease. Biochemistry. 1989 Jun 27; 28(13):5334-43.
Score: 0.001
-
Molecular cloning and characterization of two rat renal kallikrein genes. Biochemistry. 1988 Sep 20; 27(19):7189-96.
Score: 0.001
-
Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation. J Clin Invest. 1987 Dec; 80(6):1651-9.
Score: 0.001
-
Identification and characterization of a tissue kallikrein in rat skeletal muscles. Biochem J. 1987 May 01; 243(3):773-8.
Score: 0.001